The addition of GO to induction in adults with NPM1-mutated AML evaluated in the AMLSG 09-09 trial significantly reduced the CIR compared with patients treated without GO, although an increased early death rate in induction therapy (10.3% and 5.7%, respectively), mainly due to infections (41, 42). Here, NPM1 is linked to infection.